文献速递临床试验与 GCP基础与转化研究

精准免疫治疗改善脓毒症结局:ImmunoSep随机临床试验

Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

这项在6国开展的双盲、双模拟、安慰剂对照试验将281例脓毒症患者随机分入精准免疫治疗组或安慰剂组,免疫治疗依据巨噬细胞活化样综合征或脓毒症诱导的免疫麻痹进行分层给药。第9天SOFA评分较基线下降至少1.4分的比例,精准免疫治疗组为35.1%(46/131),安慰剂组为17.9%(26/145),差异17.2%(95%CI 6.8%至27.2%,P=0.002);28天死亡率两组无统计学显著差异。

要点

  • 精准免疫治疗组第9天SOFA评分下降至少1.4分者占35.1%,安慰剂组占17.9%。
  • 28天死亡率在精准免疫治疗组与安慰剂组之间无统计学显著差异。
  • 巨噬细胞活化样综合征组用阿那白滞素后贫血发生率增加,免疫麻痹组用重组人干扰素γ后出血发生率增加。

核心结论

  • 在脓毒症患者中,针对巨噬细胞活化样综合征和脓毒症诱导的免疫麻痹的精准免疫治疗,与安慰剂相比改善了第9天的器官功能障碍。

研究设计与样本

  • 随机、双盲、双模拟、安慰剂对照临床试验,在6个国家开展。
  • 纳入标准为符合Sepsis-3定义的脓毒症,且伴有社区获得性或医院获得性肺炎、呼吸机相关性肺炎或菌血症合并脓毒症,并表现为巨噬细胞活化样综合征(血铁蛋白>4420 ng/mL)或脓毒症诱导的免疫麻痹(血铁蛋白≤4420 ng/mL且CD45/CD14单核细胞上人类白细胞抗原DR受体<5000)。
  • 首例患者于2021年8月5日入组,末次随访为2024年4月29日。
  • 672例患者接受资格评估,281例被随机分组,276例纳入主要分析人群(平均[SD]年龄70[13]岁;女性93例[33.7%];基线SOFA评分中位数9[IQR 7-11])。

主要发现

  • 第9天SOFA评分下降至少1.4分的终点在精准免疫治疗组131例中46例(35.1%)达到,在安慰剂组145例中26例(17.9%)达到,差异17.2%(95%CI 6.8%至27.2%;P=0.002)。
  • 28天死亡率在精准免疫治疗组与安慰剂组之间无统计学显著差异。
  • 共报告1069起严重治疗中出现的不良事件(88.8%);阿那白滞素组贫血发生率增加,重组人干扰素γ组出血发生率增加。

关键数值与推荐

  • 主要终点为第9天平均序贯器官衰竭评估(SOFA)评分较基线下降至少1.4分。
  • SOFA评分评估6个器官系统,每系统0分(无功能障碍)至4分(衰竭),总分0分(正常)至24分(最严重形式的多器官衰竭)。
  • 巨噬细胞活化样综合征定义为血铁蛋白>4420 ng/mL;脓毒症诱导的免疫麻痹定义为血铁蛋白≤4420 ng/mL且CD45/CD14单核细胞上人类白细胞抗原DR受体<5000。
  • 精准免疫治疗组中巨噬细胞活化样综合征患者接受静脉阿那白滞素加皮下安慰剂,免疫麻痹患者接受皮下重组人干扰素γ加静脉安慰剂;安慰剂组接受静脉和皮下安慰剂;治疗最长15天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sepsis is heterogeneous, and the optimal strategy for tailoring immunotherapy is uncertain. OBJECTIVE: To investigate whether precision immunotherapy guided by the presence of macrophage activation-like syndrome or sepsis-induced immunoparalysis improves organ dysfunction by day 9. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, double-dummy, placebo-controlled clinical trial conducted in 6 countries. Patients with sepsis, defined by Sepsis-3, were included if they had community-acquired or hospital-acquired pneumonia or ventilator-associated pneumonia or bacteremia and sepsis and had displayed either macrophage activation-like syndrome (blood ferritin >4420 ng/mL) or sepsis-induced immunoparalysis (blood ferritin ≤4420 ng/mL and <5000 human leukocyte antigen DR receptors on CD45/CD14 monocytes). The first patient was enrolled August 5, 2021, and the last follow-up, April 29, 2024. INTERVENTIONS: Eligible patients were randomized to receive standard care and precision immunotherapy or standard care and placebo. Those in the precision immunotherapy group with macrophage activation-like syndrome received anakinra intravenously (IV) and placebo subcutaneously, and those with sepsis-induced immunoparalysis received subcutaneous recombinant human interferon gamma and IV placebo. Those in the placebo group received both IV and subcutaneous placebo. Treatment was administered for up to 15 days. MAIN OUTCOMES AND MEASURES: The primary end point was a decrease of at least 1.4 points in the mean Sequential Organ Failure Assessment (SOFA) score from baseline by day 9. The SOFA score evaluates 6 organ systems, ranging from 0, no dysfunction, to 4, failure, and the total score ranges from 0, normal, to 24, most severe form of multiorgan failure. Key secondary outcomes included 28-day mortality. RESULTS: Of 672 patients assessed for eligibility, 281 were randomized and 276 were included in the primary analysis population (mean [SD] age, 70 [13] years; 93 females [33.7%]; median baseline SOFA score, 9 [IQR, 7-11]). The SOFA decrease end point was attained by 46 of 131 patients (35.1%) in the precision immunotherapy group and by 26 of 145 patients (17.9%) in the placebo group (difference, 17.2% [95% CI, 6.8% to 27.2%]; P = .002). Mortality at 28 days was not statistically significantly different between groups. A total of 1069 serious treatment-emergent adverse events (88.8%) were reported; increased incidence of anemia was noted in the anakinra group; and hemorrhage in the recombinant human interferon gamma group. CONCLUSIONS AND RELEVANCE: Among patients with sepsis, precision immunotherapy targeting macrophage activation-like syndrome and sepsis-induced immunoparalysis improved organ dysfunction by day 9 compared with placebo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04990232.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Giamarellos-Bourboulis EJ, Kotsaki A, Kotsamidi I, et al. Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial. JAMA. 2026. PMID: 41359996. doi:10.1001/jama.2025.24175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。